HERZLIYA, Israel, January 29, 2026 — Regentis Biomaterials Ltd. announced a significant expansion of its U.S. clinical site network for the ongoing pivotal Phase III clinical trial of GelrinC®, an investigational regenerative therapy for knee cartilage repair. The expansion adds several leading academic and clinical orthopedic centers across the United States, a move expected to accelerate patient enrollment, enhance data quality, and strengthen the company’s overall clinical execution strategy as enrollment surpasses 50% completion in the FDA-regulated study.
Science Significance
The expansion underscores the growing momentum behind GelrinC®, a cell-free, off-the-shelf hydrogel implant designed to enable synchronized cartilage regeneration. Unlike traditional cartilage repair approaches that rely on cells or complex multi-step procedures, GelrinC leverages a biomaterial-driven regenerative mechanism, allowing native cells to restore damaged cartilage in a controlled manner. By enrolling patients at high-volume orthopedic centers with deep expertise in cartilage repair, joint preservation, and sports medicine, Regentis is strengthening the scientific rigor of its trial and ensuring robust, reproducible clinical evidence to validate long-term outcomes such as pain relief, functional recovery, and cartilage regeneration durability.
Regulatory Significance
From a regulatory perspective, this announcement reflects strong clinical trial governance and GxP-aligned execution. The Phase III study represents a pivotal FDA trial, positioning GelrinC as a potential first-in-class regenerative orthopedic therapy for the U.S. market. Expanding the site network supports regulatory expectations for enrollment diversity, data integrity, and trial scalability, all critical factors in FDA review. With GelrinC already holding CE Mark approval in the European Union, the U.S. trial serves as the final regulatory milestone toward potential FDA clearance, reinforcing the product’s global regulatory pathway.
Business Significance
Advertisement
Strategically, the site expansion strengthens Regentis’ commercial readiness following its recent IPO. By partnering with nationally recognized institutions such as NYU Langone, Rush University Medical Center, and The Ohio State University Wexner Medical Center, Regentis is aligning its clinical program with key opinion leaders who can influence future adoption. The company is targeting a U.S. addressable market of approximately 470,000 knee cartilage repair cases annually, where no comparable off-the-shelf solution currently exists. Successful completion of the Phase III program would position GelrinC as a disruptive entrant in the cartilage repair market, offering payers and providers a cost-effective, scalable alternative to existing surgical options.
Patients’ Significance
For patients, the expanded trial network translates directly into greater access to innovative regenerative treatment options. GelrinC is designed as a single, minimally invasive, 10-minute procedure, with clinical data indicating sustained pain relief and functional improvement for more than four years. The off-the-shelf nature of the product reduces procedural complexity and recovery time, addressing significant unmet needs for individuals suffering from painful focal knee cartilage injuries. By increasing enrollment capacity across diverse geographic regions, Regentis is accelerating the potential timeline for bringing this therapy to patients in the United States.
Policy Significance
At a broader policy level, the trial expansion aligns with ongoing efforts to advance regenerative medicine within regulated clinical frameworks. FDA support for well-designed pivotal trials in orthopedics reflects growing recognition of biomaterial-based regenerative therapies as a means to reduce long-term healthcare costs associated with chronic joint disease and disability. The study also supports healthcare system priorities focused on outcomes-based care, faster recovery, and reduced surgical burden—key considerations for policymakers, payers, and healthcare systems managing aging populations.
With enrollment momentum building and a strengthened network of elite orthopedic centers, Regentis Biomaterials is reinforcing its commitment to delivering high-quality clinical evidence for GelrinC®. The expanded Phase III infrastructure not only accelerates trial completion but also lays the groundwork for future clinical programs built on the company’s Gelrin platform technology. As regulatory milestones approach, GelrinC stands poised to redefine the standard of care in knee cartilage repair through science-driven, patient-centered regenerative innovation.
Source: Regentis Biomaterials Ltd press release
